Federal prosecutors have charged Jaynier Moya, MD, co-owner and principal investigator at Pines Care Research Center in Pembroke Pines, Florida, along with clinical research coordinators Luis Montano, Yuniarka Garcia, and Alexandra Olivera, in connection with an alleged scheme to falsify data in industry-sponsored drug trials.
According to charging documents, the alleged misconduct began no later than 2019. Prosecutors allege the defendants created records suggesting study participants had taken investigational medications and undergone protocol-required testing when they had not. Prosecutors also allege that identification documents from people who did not participate in the trials were used to create false participant records and test results.
The significance of the case is that prosecutors allege the falsified data did not remain confined to site-level records. According to the Justice Department, the alleged scheme caused falsified test data to be submitted into clinical trial database systems used to evaluate prospective new drugs.
The indictment and criminal information are allegations, and all defendants are presumed innocent unless proven guilty beyond a reasonable doubt in court. Still, the case underscores why data integrity at research sites is central to confidence in clinical development: downstream analyses and regulatory evaluation depend on the accuracy of information generated during trial conduct.
“The trials were designed to test prospective new drugs to evaluate their safety and efficacy for potential approval by the FDA,” according to the US Department of Justice.